Equity Research, Broker Reports, and media content on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. We currently have 0 research reports from 0 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 0.00/0.00
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 0m
  • Latest PE (hist):
  • Div Yield:

Latest News/RNS

(more news)
Date Source Announcement
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • Providers covering

    Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

  • 18 Oct 21
Tristel - FY 2021 results

Full-year results were in line with the trading update of 21 July, with revenues of £31m (-2%), reflecting the impact of COVID-19 on out-patient procedure rates, resulting in 14% and 24% declines in adjusted EBITDA and pre-tax profit, respectively. Lower than expected procedure growth rates and the decision to discontinue non-core (non-chlorine dioxide products) reduces forecast revenues by c.£3m to £33m in FY 2022. However, higher gross profit and tight control of costs (+6%) results in an unch

Companies: Tristel Plc
  • 20 Oct 21
Hybridan Small Cap Feast 20/10/2021

Joiners No Joiners Today. Leavers No Leavers Today. What’s cooking in the IPO kitchen? Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz. Offer TBA. Due early Nov. Life Science REIT to join AIM raising up to £100m. This will be the first London listed real estate investment trust (REIT) focused on UK life science properties providing investors with exposure

Companies: SYS1 ARE SO4 SNG TMG TMT OHG IDE KIBO MRL

  • 22 Oct 21
hRPC update in Q122 plus exosome brain research

Recruitment resumed the Phase 2a trial of the lead programme hRPC in retinitis pigmentosa (RP) with the treatment of the first UK-patient in Oxford. The protocol gives greater infection control after the safety issue (a possible infection) in June. Five patients were treated up to mid-October and the remaining four could be treated by December 2021. By late March 2022, ReNeuron expects to give an interim update. The full data set should be available around mid-2022. This will enable regulatory d

Companies: ReNeuron Group plc
  • 18 Oct 21
Hybridan Small Cap Feast 18/10/2021


Companies: WAND SDX SEMP BMK LVCG MOS ACC

  • 22 Oct 21
Hybridan Small Cap Feast 22/10/2021

Joiners No Joiners Today Leavers No Leavers Today What’s cooking in the IPO kitchen? Arrow Exploration Corp. (AIM: AXL ; TSXV: AXL) , the oil and gas exploration and production company, has conditionally raised approximately £8.8m and is due to complete its dual listing on AIM on 25 Oct. Market cap c£13.1m. Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz.

Companies: ZYT CIC DMTR GILD LMS MMAG PYC SMRT SBI

  • 22 Oct 21
Cenkos: IXICO Plc -- Contract update

IXICO has announced that one of its clients has put an indefinite halt on a clinical trial for which the company was providing its artificial intelligence medical image analysis. The halt is the result of unexpected preclinical data. IXICO had expected the contract to deliver £0.8m of revenues in FY22E and it represented £3.3m of the £18.8m order book as of the close September 2021. While this news is disappointing, clearly the trial halt has no reflection on the capability of IXICO's technology

Companies: IXICO Plc
  • 18 Oct 21
Cenkos: IXICO Plc -- Upgraded trading update

IXICO has provided an upgraded trading statement for FY21E following its previous update in August 2021. Revenues are now expected to be £9.2m (vs £8.7m previously), broadly in line with FY20A, which we see as a strong result given the pandemic and Huntington's Disease (HD) trials de-scope. EBITDA is expected to be materially ahead of FY20A's £1.3m, supported by strong Q4/21 trading, cost control and positive one-offs. The company has ended FY21 with a strong order book (£18.8m) and cash positio

Companies: IXICO Plc
  • 21 Oct 21
CareTech (CTH) - Full year update illustrates further progress; FY 2021E EPS +3.2%

CareTech is a specialist social care and educational services provider. This morning, the group has announced an update for the year to 30 September pointing to the fact that results will be in line with market expectations. The net debt position of £259m illustrates a further reduction since the end of H1 (31 March £263.1m) and implying a reduction to 2.7x adjusted EBITDA. During the year, seven new developments have opened, with a further eight properties purchased in H2. The group's freehold

Companies: CareTech Holdings PLC
  • 30 Sep 21
Cenkos: SkinBioTherapeutics Plc -- AxisBiotix-Ps launch announced

SkinBioTherapeutics has announced it will launch its lead commercial product, AxisBiotix-Ps on World Psoriasis Day, 29 October 2021. To support the launch, the company has begun to receive, and store finished product in the Netherlands (close to its manufacturing partner) ahead of initial launches in the UK and US. Clearly the launch of its first product is a significant step for SkinBioTherapeutics, marking the transition from development company to commercial operation. We are encouraged by th

Companies: SkinBioTherapeutics Plc
  • 30 Sep 21
Synairgen - Interims – not long to wait for Phase III data readout

Synairgen reported interim results to 30 June in which the adjusted net loss was £32.8m with period-end cash of £46.2m. Substantial pre-commercial progress and manufacturing activities have made in the half, although slower country approvals for trial sites will result in Phase III data readout slipping into Q1 2022. With increasing evidence of the need for a broad-spectrum antiviral delivered to the lungs and recognition that vaccines don’t provide complete protection against hospitalisations d

Companies: Synairgen plc
  • 13 Oct 21
Hybridan Small Cap Feast 13/10/2021

Joiners No Joiners Today. Leavers Cambria Autos has left the AIM following a takeover. What’s cooking in the IPO kitchen? Light Science Tech Holdings, the controlled environment agriculture technology and contract electronics manufacturing Group to join AIM. Raising £5m. Expected mkt cap £17.4m. Due 15 Oct. Harmony Energy Income Trust to join the Specialist Fund Segment of the Main Market raising up to £230m. The Company's investment objective is to provide investors with an attractive and susta

Companies: VRS ORPH SNG MRL EBQ AVG

  • 16 Oct 17
N+1 Singer - Futura Medical - Market research supports the commercial potential of Eroxon®

The positive market research results for Eroxon®, released this morning, provides further support for the company’s ongoing partnering efforts. We continue to believe that MED2002 is a differentiated product with significant potential in both prescription and OTC markets, and look forward to further PK data followed by Phase III start in H1 2018.

Companies: Futura Medical plc
  • 10 Aug 20
Milking the COVID-19 opportunities

Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled growth in the Branded segment. Combined with a favourable product-mix, the operating margin was up 1.5ppt. In the near term, new launches across segments should provide some respite against the ongoing pricing pressure. Given the company’s thin R&D pipeline and a robust balance sheet, M&A (probably in the biosimilars space) seems on the cards.

Companies: Hikma Pharmaceuticals Plc
  • 18 Dec 20
Partnership with Tabula Rasa HealthCare’s DoseMeRx® for personalised docetaxel model and further Merck contracts.

The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions yesterday announced it has entered into a partnership with Tabula Rasa HealthCare® (TRHC) (NASDAQ: TRHC), a healthcare technology Company advancing the field of medication safety. Through this initiative, Physiomics' personalised docetaxel model will be integrated into TRHC's market-leading precision dosing solution, DoseMeRx®. Both parties expect positiv

Companies: Physiomics Plc
  • 09 Feb 21
Small Cap Feast

Samarkand Group Limited, the cross-border eCommerce technology and retail group opening up the world's largest market for brands and retailers, intends to IPO on the Apex Segment Aquis Stock Exchange Growth Market. Admission is targeted for March 2021. Cellular Goods a UK-based provider of premium consumer products based on biosynthetic cannabinoids announced its intention to join the main market (standard) this spring. Target valuation £20m raising c. £8m “to finalise the development and launch

Companies: SYM ABDX NBI BPM TND BRCK PRES ENET CDGP